Published in Antimicrob Agents Chemother on February 01, 2001
In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis (2003) 1.16
Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis (2003) 1.15
In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother (2003) 1.14
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob Agents Chemother (2003) 1.11
Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother (2003) 1.04
In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother (2002) 0.99
In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob Agents Chemother (2002) 0.95
In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities. Antimicrob Agents Chemother (2003) 0.92
Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents. Antimicrob Agents Chemother (2003) 0.90
Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob Agents Chemother (2003) 0.89
Factors influencing fluoroquinolone resistance. Emerg Infect Dis (2003) 0.88
In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species. Antimicrob Agents Chemother (2002) 0.87
Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag (2006) 0.85
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother (2004) 0.82
Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother (2004) 0.76
Antianaerobic activity of sulopenem compared to six other agents. Antimicrob Agents Chemother (2009) 0.76
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother (1997) 2.91
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother (1999) 2.88
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother (1992) 2.53
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother (1993) 2.29
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother (1990) 2.25
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother (1994) 2.21
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother (1991) 2.11
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother (1993) 1.76
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother (1996) 1.76
Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance. Antimicrob Agents Chemother (1990) 1.75
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother (1998) 1.73
Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium. Eur J Clin Microbiol Infect Dis (1990) 1.56
Characterization of a beta-lactamase from Clostridium clostridioforme. J Antimicrob Chemother (1994) 1.47
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother (1993) 1.32
Emergence of multiply resistant pneumococci. N Engl J Med (1978) 8.32
Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J (1999) 5.88
Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood (2000) 5.34
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother (2000) 4.31
Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet (1977) 4.07
Enhanced detection of bacteremia with a new BACTEC resin blood culture medium. J Clin Microbiol (1983) 3.25
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother (1994) 3.12
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis (1999) 2.74
Antimicrobial susceptibility testing of pneumococci. 2. Determination of optimal disc diffusion test for detection of penicillin G resistance. J Antimicrob Chemother (1980) 2.73
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother (1984) 2.71
Infection caused by vancomycin-resistant Streptococcus sanguis II. Antimicrob Agents Chemother (1984) 2.66
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother (1992) 2.64
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother (1999) 2.63
Ligase chain reaction for detection of Neisseria gonorrhoeae in urogenital swabs. J Clin Microbiol (1995) 2.62
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother (1986) 2.48
Susceptibility of anaerobic bacteria to ten antimicrobial agents. Antimicrob Agents Chemother (1978) 2.45
Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis (1983) 2.41
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother (1986) 2.39
Antimicrobial susceptibility testing of pneumococci: determination of Kirby-Bauer breakpoints for penicillin G, erythromycin, clindamycin, tetracycline, chloramphenicol, and rifampin. Antimicrob Agents Chemother (1979) 2.32
Evaluation of a two-hour method for screening pathogens from stool specimens. J Clin Microbiol (1984) 2.27
Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants. J Pediatr (1994) 2.25
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother (1990) 2.25
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother (1994) 2.21
Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features. Arch Intern Med (1993) 2.21
Pleuropulmonary infections caused by Eikenella corrodens. Rev Infect Dis (1992) 2.20
Resistance mechanisms of multiply resistant pneumococci: antibiotic degradation studies. Antimicrob Agents Chemother (1979) 2.17
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother (1997) 2.17
Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother (1995) 2.13
Comparison of three methods for anaerobe identification. J Clin Microbiol (1983) 2.12
Four methods for identification of gram-negative nonfermenting rods: organisms more commonly encountered in clinical specimens. J Clin Microbiol (1980) 2.09
In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.04
Proctitis associated with Neisseria cinerea misidentified as Neisseria gonorrhoeae in a child. J Clin Microbiol (1985) 1.90
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 1.90
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother (1997) 1.87
Comparative evaluation of the API 20S system and the automicrobic system gram-positive identification card for species identification of streptococci. J Clin Microbiol (1984) 1.82
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother (1998) 1.79
Evaluation of the rapid strep system for species identification of streptococci. J Clin Microbiol (1984) 1.78
Evaluation of the rapid NFT system for identification of gram-negative, nonfermenting rods. J Clin Microbiol (1984) 1.78
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother (1993) 1.76
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 1.75
Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance. Antimicrob Agents Chemother (1990) 1.75
Pancreatic abscess associated with Achromobacter group Vd biovar 1. J Clin Microbiol (1980) 1.75
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother (1998) 1.73
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother (2010) 1.72
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.70
Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J Antimicrob Chemother (1993) 1.69
The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics (1998) 1.65
A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program. Clin Infect Dis (1999) 1.64
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.62
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob Agents Chemother (1997) 1.61
Evaluation of the E-Test for susceptibility testing of pneumococci. Diagn Microbiol Infect Dis (1992) 1.59
Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother (1995) 1.58
Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J (2000) 1.57
Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis. J Antimicrob Chemother (1983) 1.56
Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium. Eur J Clin Microbiol Infect Dis (1990) 1.56
Accuracy and reproducibility of a four-hour method for anaerobe identification. J Clin Microbiol (1985) 1.54
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother (1996) 1.51
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother (1994) 1.51
Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother (2001) 1.50
Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother (1994) 1.49
Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother (2000) 1.49
Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother (2000) 1.48
Characterization of a beta-lactamase from Clostridium clostridioforme. J Antimicrob Chemother (1994) 1.47
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob Agents Chemother (1996) 1.46
Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother (1994) 1.44
Pathogenic mechanisms of a non-agglutinable Vibrio cholerae strain: demonstration of invasive and enterotoxigenic properties. Infect Immun (1977) 1.43
Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis (2001) 1.42
Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours. J Clin Microbiol (1996) 1.41